An Introduction to Systemic Sclerosis
Systemic sclerosis (SSc) is a rare, life-threatening, rheumatologic autoimmune disease characterised by fibrosis of the skin and multiple organ targets. Treatment strategies involve immunosuppressive and antifibrotic drugs but their efficacy is modest. Haematopoietic stem-cell transplantation reduces long-term mortality, but confers the risk of treatment-related mortality. Nintedanib has been approved to slow the rate of decline in pulmonary function in adults with interstitial lung disease associated with SSc, but does not affect skin fibrosis. Many novel therapeutic targets are emerging, including interleukin (IL) -6 (tocilizumab), IL-4 and IL-13, B cell pathology, and the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway. However, there remains no approved targeted therapies.
Browse our selection of video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences and a selection of peer-reviewed articles from the journal portfolio.
Systemic Sclerosis Content
Dinesh Khanna, ACR 2020: Ziritaxestat in Cutaneous Systemic Sclerosis
touchIMMUNOLOGY caught up with Dinesh Khanna (University of Michigan, Ann Arbor, MI, USA) to discuss the results of the NOVESA Phase 2a study of ziritaxestat in cutaneous systemic sclerosis (NCT03798366). His abstract entitled ‘A Phase 2a Randomized, Double-blind, Placebo-controlled Study of Ziritaxestat in Early Diffuse Cutaneous Systemic Sclerosis (NOVESA)’ was presented at the virtual ACR […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!